Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Corcept Therapeutics (CORT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,368,645
  • Shares Outstanding, K 114,723
  • Annual Sales, $ 251,250 K
  • Annual Income, $ 75,410 K
  • 60-Month Beta 1.28
  • Price/Sales 5.58
  • Price/Cash Flow 18.64
  • Price/Book 5.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.18
  • Number of Estimates 2
  • High Estimate 0.18
  • Low Estimate 0.17
  • Prior Year 0.14
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.10 +6.67%
on 02/22/19
13.03 -9.13%
on 03/04/19
+0.75 (+6.76%)
since 02/21/19
3-Month
9.14 +29.54%
on 02/05/19
16.08 -26.37%
on 01/16/19
-0.16 (-1.33%)
since 12/21/18
52-Week
9.14 +29.54%
on 02/05/19
20.00 -40.80%
on 05/30/18
-5.79 (-32.84%)
since 03/21/18

Most Recent Stories

More News
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CORT, CAG, VNDA and INGN

The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies...

CORT : 11.95 (+0.17%)
CAG : 25.54 (+11.53%)
VNDA : 18.38 (+2.68%)
INGN : 95.20 (+2.07%)
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Corcept Therapeutics Incorporated

Law Offices of Howard G. Smithreminds investors of the upcomingMay 13, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Corcept...

CORT : 11.95 (+0.17%)
SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) from August 2, 2017 through February...

CORT : 11.95 (+0.17%)
CORCEPT THERAPEUTICS INCORPORATED INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Corcept Therapeutics Incorporated

Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Northern District of California against...

CORT : 11.95 (+0.17%)
Corcept Therapeutics Announces Poster Presentations at the 2019 Annual Meeting of the Endocrine Society Meeting

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CORT : 11.95 (+0.17%)
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Corcept Therapeutics Incorporated To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ:CORT) of the May 13, 2019 deadline to seek the...

CORT : 11.95 (+0.17%)
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Corcept Therapeutics Incorporated

Glancy Prongay & Murray LLP ("GPM") reminds investors of the April 30, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased...

CORT : 11.95 (+0.17%)
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corcept Therapeutics Incorporated and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT)...

CORT : 11.95 (+0.17%)
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Corcept Therapeutics Incorporated

Federman & Sherwood announces that on March 14, 2019, a class action lawsuit was filed in the United States District Court for the Northern District of California against Corcept Therapeutics...

CORT : 11.95 (+0.17%)
Interesting CORT Put And Call Options For November 15th

Investors in Corcept Therapeutics Inc saw new options become available this week, for the November 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is...

CORT : 11.95 (+0.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CORT with:

Business Summary

Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol....

See More

Key Turning Points

2nd Resistance Point 12.40
1st Resistance Point 12.16
Last Price 11.95
1st Support Level 11.80
2nd Support Level 11.68

See More

52-Week High 20.00
Fibonacci 61.8% 15.85
Fibonacci 50% 14.57
Fibonacci 38.2% 13.29
Last Price 11.95
52-Week Low 9.14

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar